In women with early breast cancer (stage I, stage II), the tumor expression of HER2/neu and hormone receptors (ER, PR), which are emerging prognostic factors, could not be related to the axillary lymph node status, whether positive or negative node; table (11). And this is consistent with the clinical observations in the literature. And the data from literature suggest that HER2/neu is associated with more aggressive tumor, but its use as a determining factor in selecting the line of adjuvant therapy is still limited by the varying methods employed to detect over-expression. While the axillary lymph node status is the most consistent prognostic factor used in adjuvant therapy decision making. Patients with positive lymph nodes are offered adjuvant therapy. Meanwhile, the prognostic significance of estrogen or progesterone receptors is limited. Its optimal use is as a predictive factor for the benefit of adjuvant tamoxifen therapy. As demonstrated in the literature, all hormone receptor-positive women who warrant adjuvant systemic therapy should receive hormonal therapy unless otherwise contraindicated